| Literature DB >> 19552811 |
Carla Guerriero1, John Cairns.
Abstract
BACKGROUND: Evaluating the economic benefit of reducing negative health outcomes resulting from waste management is of pivotal importance for designing an effective waste policy that takes into account the health consequences for the populations exposed to environmental hazards. Despite the high level of Italian and international media interest in the problem of hazardous waste in Campania little has been done to reclaim the land and the waterways contaminated by hazardous waste.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19552811 PMCID: PMC2711922 DOI: 10.1186/1476-069X-8-28
Source DB: PubMed Journal: Environ Health ISSN: 1476-069X Impact factor: 5.984
Figure 1Method used for evaluating the health.
Number of fatal cases attributable to waste exposure.
| Waste index | Relative Risk | Observed cases 1994–2001 | PAPa 1994–2001 | |
|---|---|---|---|---|
| 2 | 1.05b | 53106 | 2528 | |
| 3 | 1.08b | 7853 | 580 | |
| 4 | 1.04b | 20130 | 774 | |
| 5 | 1.08b | 8459 | 698 | |
| 2 | 1.02 | 52167 | 1023 | |
| 3 | 1.08b | 7124 | 528 | |
| 4 | 1.05b | 18226 | 868 | |
| 5 | 1.12b | 7501 | 804 | |
a Population attributable proportion over 8 year follow up [18].
b p value < 0.05
Number of fatal cases of cancer attributable to waste exposure.
| Waste index | Relative Risk | Observed cases 1994–2001 | PAPa 1994–2001 | |
|---|---|---|---|---|
| 2 | 1.04b | 15989 | 615 | |
| 3 | 1.06b | 2297 | 1658 | |
| 4 | 1.05b | 6261 | 298 | |
| 5 | 1.04 | 2525 | 97 | |
| 2 | 1.05b | 11435 | 544 | |
| 3 | 1.02 | 1490 | 30 | |
| 4 | 1.04 | 4038 | 155 | |
| 5 | 1.07b | 1639 | 107 | |
a Population attributable proportion over 8 year follow up [18].
b p value < 0.05
Monetary benefits arising from waste sites reclaim.
| Item | PAP per year | Benefitsa (billion €) | Benefits per person(€) b |
|---|---|---|---|
| All causes mortality | 848 | 9.4 | 2,300 |
| All fatal cancers | 403 | 6.7 | 1,700 |
| (4.5–17.0)c | (1,100–4,400) | ||
| All cause mortality adjusted for cancer premium | 848 | 11.6 | 3,000 |
a benefits have been rounded to the nearest million.
b benefits per person have been rounded to the nearest hundred
c Lower and Upper and estimates obtained using lower and upper values suggested by the EC [25].
Monetary benefits (billion €) by time horizon over which benefits accruea.
| Item | 50 year time | 20 year time | 10 year time |
|---|---|---|---|
| All causes mortality | 17.0 | 7.0 | 4.0 |
| All fatal cancers | 8.0 | 5.0 | 3.0 |
| All cause mortality adjusted for cancer premium | 20.0 | 9.0 | 5.4 |
a all costs have been rounded to the nearest million
b Upper and Lower estimates obtained using upper and lower values suggested by the EC [25]
Figure 2Monetary benefits (billion€) assuming different latency periods and a 4% discount rate.
Figure 3Monetary benefits (billion€) assuming different latency periods and a 2% discount rate.
Monetary benefits (billion €) after accounting for the decline deaths during the after latency period.
| Item | Benefits a |
|---|---|
| All causes mortality | 10.6 |
| All fatal cancers | 7.5 |
| All cause mortality adjusted for "cancer premium" | 12.8 |
a all benefits have been rounded to the nearest million
b Upper and Lower estimates obtained using upper and lower values suggested by the EC [25]